Trial Profile
Rotation or Change of Biotherapy After TNF blocker treatment failure for axial Spondyloarthritis: The ROC-SpA study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
- Indications Spondylarthritis
- Focus Therapeutic Use
- Acronyms ROC-SPA
- 03 Oct 2022 Planned End Date changed from 1 Nov 2023 to 1 Nov 2025.
- 03 Oct 2022 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 21 Jul 2021 Planned End Date changed from 1 Nov 2021 to 1 Nov 2023.